君实生物在 2026年 ESMO 大会上公布 NEOTORCH 三期研究的最终分析结果
君实生物在 2026年 ESMO 大会上为其抗癌药物特瑞普利单抗公布了积极的 NEOTORCH 三期临床试验结果。该疗法在肺癌患者的无事件生存期和总生存期方面展示出显著改善。
Junshi Biosciences presented positive final analysis results from its Phase 3 NEOTORCH study at the ESMO Congress 2026. The study evaluated perioperative treatment using toripalimab combined with chemotherapy in patients with resectable stage II-III non-small cell lung cancer. Results demonstrated statistically significant and durable improvements in both event-free survival and overall survival rates. The favorable clinical data reinforces toripalimab's therapeutic potential as an effective treatment option for lung cancer patients. Successful late-stage trials strengthen the company's position within the global oncology biopharmaceutical sector. Continued positive clinical outcomes may pave the way for expanded regulatory approvals and commercial adoption worldwide.
AI 分析免责声明
资产影响分析由 AI 生成，仅供参考，不构成投资建议。做出投资决策前，请务必自行研究。
讨论